CRT-DL ALLIANCESBEATING CANCER THROUGH SYNERGY

CRT-DL (CRT’s Discovery Laboratories) is the only organisation with the approach, connections and expertise to forge alliances between industry and academia to translate new discoveries in cancer research. Our proven theme-based approach seamlessly combines scientific expertise, cultivates innovation and reduces risk. Through this pioneering alliance model, CRT-DL is changing the way scientists approach cancer drug discovery.

With an in-house team of drug discovery scientists, CRT-DL is able to capitalise on the research and connections of our parent organisation Cancer Research UK, and the strong links Cancer Research Technology (CRT) has established with leading clinical and academic institutions, pharmaceutical companies and biotechs worldwide.

ONE OF THE FAMILY

AN INTEGRAL PART OF THE CRUK NETWORK, WE PROVIDE UNPARALLELED ACCESS TO UK CANCER RESEARCHERS

CRT-DL is owned by Cancer Research UK (CRUK), the world’s largest charitable funder of cancer research.

CRT-DL is strategically positioned to capitalise on the breadth of science funded by CRUK:• Basic biology• Novel targets• Disease positioning• Clinical research

“Our continued alliance with CRT allows AstraZeneca to collaborate with leading scientists in the field of cancer metabolism” Dr Susan GalbraithVice-President Oncology, AstraZeneca

CANCER DRUG DISCOVERY EXPERTS

OUR SKILLS, CAPABILITIES AND EXPERTISE ARE FOCUSED ON BEATING CANCER

CRT-DL’s in-house capabilities include target and cellular biology, assay development, HTS, crystallography, DMPK and medicinal chemistry.

By combining our expertise with the best minds from academia and industry, we create the synergy required to enable successful drug discovery.

“The depth of scientific expertise at CRT-DL has been pivotal to the success of our collaboration. The team has worked seamlessly with our discovery scientists” Dr Bruce Ruggeri, Snr. Director Oncology Discovery, Teva Pharmaceuticals

A MODEL THAT WORKS

OUR THEME-BASED APPROACH IS BESPOKE, FLEXIBLE AND PROVEN

CRT-DL has established major industry partnerships with:

Our approach enables the development of bespoke cancer alliances around themed areas of cancer biology, target class and platform technologies.

$500M OF CANCER RESEARCH ONE POINT OF CONTACT

WE SIMPLIFY INTERACTIONS TO ENSURE ALLIANCES HIT THE GROUND RUNNING

“This is the first time we’ve had all of the academic networks fully established from the get-go.” Dr Steve Tregay, President and CEO, FORMA Therapeutics

Our alliances are supported by CRT’s experienced business development and legal teams.

With frameworks already in place with CRUK-funded institutions, we act as a single point of contact.

FURTHER INFORMATION

To discuss your alliance with CRT-DL, please contact the team:

discovery@cancertechnology.com+44 (0)20 3469 6300www.cancertechnology.com